Adamas Appoints Michael F. Bigham to Board of Directors
September 22 2016 - 3:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the
appointment of Michael F. Bigham, Chairman and Chief Executive
Officer of Paratek Pharmaceuticals, Inc., to its Board of
Directors. Mr. Bigham has broad management experience with
over 25 years of senior leadership in the biotechnology industry.
“We welcome Michael to our board and look forward to his
contributions as we transition Adamas into an organization with
multiple commercial opportunities,” stated Gregory T. Went, Ph.D.,
Chairman and Chief Executive Officer of Adamas Pharmaceuticals,
Inc.
“I remain impressed with the unique approach Adamas uses to
identify treatment opportunities and its innovative way of
developing new medicines,” stated Michael Bigham. The company
has generated data showing significant activity in three important
CNS diseases, with the potential for new opportunities on the
horizon. I am delighted to be joining this dedicated and
experienced team at such an exciting juncture in the life of the
Company.”
In addition to serving as Chairman and Chief Executive Officer
of Paratek Pharmaceuticals, a biotechnology company focused on
novel antibiotic therapies, Mr. Bigham has had a diverse and
successful career spanning executive leadership, finance, and
operations. From 2003 to 2015, he served as partner at
Abingworth LLP, an international investment group dedicated to life
sciences and healthcare. Prior to Abingworth, Mr. Bigham
served as Chairman and Chief Executive Officer of Coulter
Pharmaceuticals up until the company’s acquisition by Corixa.
He was an early employee at Gilead Sciences, where he served
in various capacities, including Executive Vice President of
Operations and Chief Financial Officer. Before joining Gilead
Sciences, Mr. Bigham was a Partner at Hambrecht & Quist, where
he served as Co-Head of Healthcare Investment Banking. He
currently is a member of the Board of Directors of InMediata and
has held several directorships, including Avila Therapeutics,
Magellan Biosciences, Portola Pharmaceuticals, Supernus
Pharmaceuticals, Avedro, and Valeritas. Mr. Bigham received
his B.S. from the University of Virginia and his M.B.A. at Stanford
University.
About Adamas Pharmaceuticals, Inc. Adamas
Pharmaceuticals, Inc. is driven to improve the lives of those
affected by chronic disorders of the central nervous system.
The company seeks to achieve this by modifying the pharmacokinetic
profiles of approved drugs to create novel therapeutics for use
alone and in fixed-dose combination products. Adamas is
currently developing ADS-5102, its lead wholly-owned product
candidate, for the treatment of levodopa-induced dyskinesia
associated with Parkinson’s disease and for the treatment of
walking impairment in patients with multiple sclerosis. The
company is also evaluating ADS-4101, an extended-release version of
an FDA-approved single-agent compound for the treatment of
epilepsy. In addition, under a license agreement with Forest
Laboratories Holdings Limited, an indirect wholly-owned subsidiary
of Allergan plc., the company is eligible to receive royalties from
Forest on sales of Namenda XR® and Namzaric™ beginning in June of
2018 and May of 2020, respectively. For more information,
please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co.
KGaA.
The statements contained in this press release that are not
historical fact, including those regarding Adamas’ current and
future business opportunities, are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. For
a description of the risks and uncertainties that could cause
actual results to differ from those expressed in forward-looking
statements, relating to Adamas’ business in general, see Adamas’
10-Q filed with the Securities and Exchange Commission on August 4,
2016. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release. Adamas undertakes no obligation to update
any forward-looking statement in this press release.
Contact:
Martin Forrest
VP Corporate Communications & Investor Relations
510-944-1112
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2024 to May 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2023 to May 2024